IMVT•benzinga•
B of A Securities Maintains Buy on Immunovant, Lowers Price Target to $45
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga